share_log

BTIG Maintains Buy on Health Catalyst, Lowers Price Target to $21

Benzinga Real-time News ·  Sep 26, 2022 08:13

BTIG analyst David Larsen maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $25 to $21.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment